Danaher Co. (NYSE:DHR) Shares Acquired by Avior Wealth Management LLC

Avior Wealth Management LLC lifted its position in Danaher Co. (NYSE:DHR) by 17.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,750 shares of the conglomerate’s stock after purchasing an additional 2,305 shares during the quarter. Avior Wealth Management LLC’s holdings in Danaher were worth $4,379,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in DHR. Legal & General Group Plc boosted its holdings in shares of Danaher by 2.4% in the second quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock valued at $1,490,112,000 after acquiring an additional 139,989 shares during the period. Capital Research Global Investors grew its position in Danaher by 1.0% during the 1st quarter. Capital Research Global Investors now owns 5,125,470 shares of the conglomerate’s stock worth $1,279,932,000 after purchasing an additional 52,679 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Danaher by 2.6% in the second quarter. Dimensional Fund Advisors LP now owns 3,398,649 shares of the conglomerate’s stock valued at $849,195,000 after purchasing an additional 85,081 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Danaher by 22.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after buying an additional 563,546 shares during the last quarter. Finally, Swedbank AB acquired a new stake in shares of Danaher during the first quarter worth about $676,545,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of NYSE:DHR opened at $230.76 on Wednesday. Danaher Co. has a 12 month low of $207.63 and a 12 month high of $281.70. The firm has a market capitalization of $166.67 billion, a price-to-earnings ratio of 44.04, a price-to-earnings-growth ratio of 4.24 and a beta of 0.85. The business’s 50 day simple moving average is $260.45 and its 200-day simple moving average is $260.32. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the business earned $2.02 earnings per share. Danaher’s quarterly revenue was up 3.1% compared to the same quarter last year. As a group, equities analysts forecast that Danaher Co. will post 7.51 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were issued a dividend of $0.27 per share. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.47%. Danaher’s dividend payout ratio (DPR) is currently 20.61%.

Analyst Ratings Changes

Several brokerages recently issued reports on DHR. Evercore ISI boosted their price target on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. TD Cowen lifted their target price on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. KeyCorp upped their price target on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Barclays lowered their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Finally, Raymond James cut their price objective on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, Danaher has an average rating of “Moderate Buy” and an average price target of $287.16.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This trade represents a 18.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 10.90% of the stock is currently owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.